VRDN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.82%, SMA50 -5.34%, SMA200 29.14%). The stock’s 14-day RSI is 47.3 (neutral), while the ATR of 1.53 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.0% below its high and over 197.88% above its low. Average 10-day trading volume of 2.59 million shares is slightly above the 3-month average of 1.86 million, indicating heightened recent market interest.

Viridian Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.85. This means the shares are trading below this model’s fair value.

Viridian Therapeutics, Inc. generated EPS of -$3.53 over the past year. Five-year average earnings growth is 31.28%. Wall Street analysts project EPS growth of 24.01% annually over the next five years. The latest quarter delivered EPS of -$1.05. The next quarter is forecast at -$0.98. Next year's EPS is expected at $13.21. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 15 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $61.00 to $20.00. The high target offers 198.0% upside. The low target suggests -2.3% downside. The mean target is $36.56. This offers 78.6% upside. Viridian Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 1.94%. The prior quarter beat by -15.09%. Over the last six quarters, Apple has recorded several small beats. These include -8.42% in May 06, 2025.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) closed at $20.47 USD, losing -$0.19 (-0.92%) from the previous close of $20.66. The stock is currently mid-range between its 52-week high and low $13.18 and $34.29. With a market capitalization of about $2.32 billion, Viridian Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 1.86 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Viridian Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephen F. Mahoney, the company employs approximately 252 people and listed since June 18, 2014. Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses.

Viridian Therapeutics, Inc. has 113.29 million shares outstanding. The public float is 100.79 million shares, elevated short interest at 17.60% of float. This equals 19.23 million shares. The short ratio is 10.14 days. Institutional investors hold 127.09% of the float. Insiders own 0.17%. Fairmount Funds Management LLC holds 5.09 million shares, Frazier Life Sciences Public Fund, L.P. has 1.51 million shares and Fairmount Healthcare Fund II L.P. has 1.36 million shares. Over the past six months, insider transactions show balanced activity. They sold 10.00 thousand shares across 1 transactions.

Viridian Therapeutics, Inc. trades at a P/E ratio of -5.8, slightly below the S&P 500 average, with a price-to-sales ratio of 32.6 and a price-to-book ratio of 3.34 trading at moderately above to book value. The P/FCF stands at -6.92, also below market averages.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are flat 4.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Viridian Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.8. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $37.22, suggesting 81.83% upside. Our AI forecast model points to short-term weakness (-5.62% over two weeks), a medium-term rise (13.14% over three months), and a longer-term gain (24.82% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Viridian Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.62%, with price expected at $19.32 by October 09, 2026, within a range of $18.68 to $19.99 3-Month Outlook: Projected rise of 13.14%, reaching $23.16 by December 24, 2026, with a range of $21.52 to $24.58. 1-Year Outlook: Projected gain of 24.82%, with price at $25.55 by September 24, 2027, within a range of $23.88 to $27.34.